Product Listing

AVENIO ctDNA Analysis Kits V2


AVENIO ctDNA Analysis Kits V2 are a portfolio of three NGS liquid biopsy assays for oncology research. Using a streamlined workflow to evaluate ctDNA extracted from plasma, these assays provide an end-to-end solution for tumor profiling, longitudinal monitoring of tumor burden, and minimal residual disease (MRD) detection.

Key Advantages of AVENIO ctDNA Analysis Kits V2
  • Matched ctDNA and tissue panels (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis
  • Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports
  • Streamlined, end-to-end research workflow from extraction to analysis and reporting in five days

End-to-end research workflow from extraction to reporting in five days

end-to-end workflow from extraction to reporting


  1. National Comprehensive Cancer Network.  Accessed August 2, 2023.
  2. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.
  3. Data on file with Roche.

For Research Use Only. Not for use in diagnostic procedures.

Found 0 results in